MVC amended an existing agreement with US NIH on September 18th to expand dengue vaccine market territories from 17 countries to 26 countries in order to include Brunei, Cambodia, Laos, Myanmar, Papua New Guinea, and high dengue incidence areas like Sri Lanka, Bangladesh, Nepal and Bhutan.
After the amendment, MVC is able to develop, manufacture, sell, and sublicense dengue vaccines in most Southeast Asia, South Asia, and Middle East countries, covering 1/3 of global population of approximately 2.47 billion people. According to WHO, dengue is prevalent in almost all tropical areas including South East Asia, South Asia, Central and South America.
MVC is planning to initiate a multi-regional and multi-central phase 3 clinical trial in Taiwan and South East Asia. In the meantime, MVC will initiate a proof-of-concept (POC) phase 2 clinical trial this year to verify vaccine's efficacy in the elderlies.